Log in to your Inderes Free account to see all free content on this page.

Biosergen

0.482

SEK

-7.31 %

Less than 1K followers

BIOSGN

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-7.31%

-25.62%

+60.67%

-10.74%

-9.06%

+36.93%

-81.37%

-

-86.96%

Biosergen is a biotechnology company. The company specializes in the research and development of various pharmaceuticals. The product portfolio includes, for example, the company's product BSG005, a fungicidal pharmaceutical in the clinical phase. In addition to the main business, service and associated ancillary services are also offered. The company operates in Norway. Biosergen was founded in 2004 and is headquartered in Solna.

Market cap

113.18M SEK

Turnover

319.35K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

20.8.

2025

Interim report Q2'25

19.11.

2025

Interim report Q3'25

All

Press releases

3rd party

ShowingAll content types

Regulatory press release6/11/2025, 10:01 AM

Bulletin from the annual general meeting in Biosergen AB (publ)

Press release5/23/2025, 8:00 AM

Carlsquare: Research update Biosergen: Stable quarter with exciting news around the corner

Press release5/21/2025, 1:47 PM

BioStock: Biosergen advances antifungal drug with strong Q1 results

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release5/21/2025, 6:30 AM

Biosergen AB: Biosergen publishes interim report for the first quarter 2025

Press release5/12/2025, 11:45 AM

BioStock: Biosergen taps antifungal expert as board member

Regulatory press release5/9/2025, 1:14 PM

Biosergen AB: Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives

Regulatory press release5/9/2025, 1:12 PM

Notice of annual general meeting in Biosergen AB

Press release5/9/2025, 12:23 PM

Biosergen AB: BioStock: Biosergen takes aim at climate-driven fungal infections

Press release5/2/2025, 1:17 PM

Biosergen AB: BioStock: Biosergen's CEO on the latest advancements

Regulatory press release4/30/2025, 8:30 AM

Biosergen AB: Biosergen publishes 2024 annual report

Press release3/7/2025, 2:44 PM

Carlsquare: Research update Biosergen: Continued success in India and cash injection

Press release3/7/2025, 10:15 AM

Biosergen AB: BioStock: Biosergen scales up for future wins

Regulatory press release3/5/2025, 7:30 AM

Biosergen AB: Biosergen publishes interim report for fourth quarter 2024

Press release2/11/2025, 11:25 AM

Carlsquare: Carlsquare Equity Research interview with Biosergen

Press release2/7/2025, 7:36 AM

Biosergen AB: BioStock: Biosergen's CEO: "These findings open up new possibilities"

Regulatory press release2/4/2025, 9:44 AM

Biosergen AB: Biosergen Successfully Completes Second Cohort of BSG005 Clinical Trial, Gaining Conclusive Proof-of-Concept Data, and Confirms 2025 Objectives

Regulatory press release12/20/2024, 12:40 PM

Biosergen AB: Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial

Regulatory press release12/5/2024, 10:29 AM

Biosergen AB: Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3

Regulatory press release12/3/2024, 7:22 PM

Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3

Regulatory press release12/3/2024, 7:19 PM

Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.